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RESEARCH ARTICLE Open Access
Comparative effectiveness of abatacept
versus tocilizumab in rheumatoid arthritis
patients with prior TNFi exposure in the US
Corrona registry
Leslie R. Harrold1*, George W. Reed1,2, Daniel H. Solomon7, Jeffrey R. Curtis3, Mei Liu2, Jeffrey D. Greenberg2,4
and Joel M. Kremer5,6
Abstract
Background: We compared the effectiveness of abatacept (ABA) vs tocilizumab (TCA) in tumor necrosis factor
inhibitor (TNFi) experienced patients.
Methods: We identified rheumatoid arthritis (RA) patients from a large observational US cohort (1 January 2010–31
May 2014) who had discontinued at least one TNFi and initiated ABA or TCZ in moderate or high disease activity based
on the Clinical Disease Activity Index (CDAI) and had no prior exposure to the comparator drug. Using propensity score
matching (1:1) stratified by prior TNF use (1 TNFi vs ≥2 TNFis), effectiveness at 6 months after initiation was evaluated.
Mean change in CDAI over 6 months following initiation was the primary outcome, with secondary outcomes of
achievement of low disease activity/remission (CDAI ≤ 10) and mean change in modified Health Assessment
Questionnaire (mHAQ) score.
Results: The 264 pairs of propensity score-matched ABA and TCZ initiators were well matched with no substantial
differences in the baseline characteristics, defined as standardized differences >0.1 in the stratification. Both treatment
groups had similar mean change in CDAI at 6 months (–11.3 in ABA vs –9.9 in TCZ; mean difference –1.27, 95% CI –3.
65, 1.11). Similar proportions of both treatment groups achieved low disease activity/remission (adjusted odds ratio for
ABA vs TCZ 0.99, 95% CI 0.69, 1.43). Mean change in mHAQ was –0.12 in ABA initiators vs –0.11 in TCZ initiations (mean
difference –0.01, 95% CI –0.09, 0.06).
Conclusions: Patients receiving either ABA or TCZ had substantial improvement in clinical disease activity. In this
propensity score-matched sample, similar outcomes were observed for both treatment cohorts.
Keywords: Rheumatoid arthritis, Disease-modifying anti-rheumatic drugs (biologic), Tocilizumab, Abatacept, Treatment
Background
Rheumatoid arthritis (RA) is a chronic, inflammatory
disease characterized by persistent synovitis and associ-
ated with pain, functional disability, and decreased qual-
ity of life as well as increased risk of death affecting an
estimated 1.3 million Americans [1, 2]. The goal of ther-
apy is to reduce disease activity and improve clinical out-
comes. The current treatment paradigm is to first use
conventional disease-modifying anti-rheumatic drugs
(cDMARDs) followed by step-up to combination
cDMARD therapy or initiation of a biologic [3–5]. Typic-
ally, a tumor necrosis factor inhibitor (TNFi) is the first
biologic class initiated [6]. While this class of drugs is as-
sociated with improvement in the signs and symptoms of
RA, it has been shown both in large randomized con-
trolled trials (RCTs) and in everyday clinical practice that
as many as 30–40% of patients develop an inadequate re-
sponse to TNFis [7–10]. This inadequate response may be
related to either primary nonresponse (lack of response
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after initiation) or a secondary nonresponse which is treat-
ment failure due to drug resistance or intolerance.
However, there is conflicting information regarding
which should be the next agent to manage a patient who
has had an inadequate response to a TNFi. There have
been inconsistent results regarding the benefits of chan-
ging mechanism of action in observational data as a gen-
eral approach, or whether targeting a specific pathway
after failure of a TNFi will optimize outcomes. For ex-
ample, improved outcomes were demonstrated in com-
parisons of rituximab vs a subsequent TNFi [11–14] but
not in abatacept (ABA) initiators vs a subsequent TNFi
[15]. More recently a RCT found greater effectiveness
with use of non-TNFi biologics as compared with a sec-
ond anti-TNF drug in TNF inadequate responders [16].
Given the absence of head-to-head RCTs comparing
the non-TNFi biologics in patients with inadequate re-
sponse to an anti-TNF agent, comparative effectiveness
studies using observational data from registries can be
employed [17]. To address the limitations of observa-
tional studies, such as selection bias, propensity score
methodology is commonly employed [15, 18, 19]. We
used propensity score matching to compare the clinical
effectiveness of tocilizumab (TCZ) vs ABA among RA
patients with previous anti-TNF exposure in a large US
cohort of RA patients using the Consortium of Rheuma-
tology Researchers of North America (Corrona) registry.
Specifically, we sought to compare change in disease ac-
tivity, achievement of low disease activity (LDA), and
change in function over 6 months.
Methods
Data source
The Corrona registry is an independent, prospective,
observational cohort of patients with RA recruited at
>160 private and academic practice sites across 40
states in the United States; additional details have been
published previously [20]. As of 30 May 2015, data on
more than 40,989 patients with RA have been collected.
Corrona’s database includes information about 303,260
patient visits and approximately 130,699 patient-years
(PY) of follow-up observation time, with a mean time
of patient follow-up of 3.87 years (median, 2.99 years).
Data are collected from both patients and their treating
rheumatologists, who gather information on disease
duration, prognosis, disease severity and activity, med-
ical comorbidities, use of medications including bio-
logics, cDMARDs, and prednisone, and adverse events.
Follow-up assessments are requested at least as often as
every 6 months and completed during routine clinical
encounters. For this national study, approvals for data
collection and analyses were obtained from a central in-
stitutional review board (New England Institutional Re-
view Board) for private practice sites participating
within Corrona. For the <20% of sites that are affiliated
with an academic medical center, local institutional review
boards were the Institutional Review Board of record.
Study population
Data were collected from patients with RA from the
Corrona registry who initiated TCZ or ABA on or after
1 January 2010. The study population was limited to pa-
tients who had received ≥1 TNFi and no prior use of the
comparator drug. Patients must have had the following
data available to be included in the study: date of the
ABA or TCZ initiation; follow-up visit at 6 months (win-
dow 5–10 months); and Clinical Disease Activity Index
(CDAI) measurements at baseline and 6-month follow-
up visit. For patients whose initiation occurred between
visits, a prior visit (within 4 months of initiation) was
used for baseline characteristics. Patients in LDA or re-
mission at initiation based on the CDAI were excluded
from the study (Fig. 1). All patients provided written in-
formed consent prior to participation.
Measures and data collection
Data from Corrona were collected during the study
period (1 January 2010–31 May 2014) from physician
and patient questionnaires completed during routine
clinical encounters. Biologic, cDMARD, and prednisone
use was recorded at the time of the clinical encounter as
well as 28-joint tender and swollen joint counts, phys-
ician and patient global assessments of disease activity,
patient assessment of pain, and modified Health Assess-
ment Questionnaire (mHAQ) score assessing physical
function [21]. Data on demographics, insurance status,
comorbid conditions, RA disease characteristics, and RA
medications were available for ≥99% of patients.
Drug exposure cohorts
To balance for predisposing factors that may increase a
patient’s likelihood of receiving either ABA or TCZ, a
propensity score [22, 23]—or the probability of treat-
ment selection—was calculated for each eligible patient
using baseline (at the time of drug initiation) patient
demographics (age, sex, and insurance type), disease
characteristics (rheumatoid factor seropositivity, American
College of Rheumatology functional class, patient and pro-
vider global assessments, disease activity, and functional
status based on the mHAQ), comorbidities (history of ser-
ious infectious event), and concurrent medications (pred-
nisone). The ABA and TCZ patients were stratified by 1
TNFi vs ≥2 prior TNFis and then matched within each
stratum based on the propensity score estimated within
each strata without replacement using calipers of 0.01.
The resulting stratified-matched population resulted in
264 matched pairs.
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Study outcomes
Responsiveness to medication treatment was defined
based on mean change in CDAI as our primary outcome
(e.g., follow-up CDAI – baseline CDAI). As secondary
outcomes, we examined the proportion of patients who
achieved LDA/remission (CDAI score ≤ 10) and change in
the mHAQ score at 6 months. Acceleration and deceler-
ation of prednisone dosing was examined (both initiation/
discontinuation as well as dose increase/decrease)
over the time period. We utilized the same parame-
ters for cDMARD initiation and discontinuation over
the study period.
Analysis and statistical methods
Patients were included regardless of switching or dis-
continuation of the medication without initiating an-
other biologic among the two comparator groups.
Baseline patient demographics and clinical and disease
characteristics were compared between the two drug-
exposure cohorts, and standardized differences were
estimated. Standardized differences provide a measure
of clinically important differences (even if there are
no statistically significant differences). A standard dif-
ference < 0.1 has been taken to indicate a negligible
difference in the mean or prevalence of a covariate
between treatment groups [22]. Response was defined
based on primary and secondary outcomes at
6 months regardless of continuation of initial treat-
ment. For those patients who discontinued the drug
without initiating another biologic, the observations
at the 6-month visit were used. For those who
switched to another agent, the last observation prior
to the switch was used as the primary analytic
approach. Additionally, we imputed nonresponse for
patients who switched biologics. However, because
the results were similar to the last observation carried
forward approach, we do not present the results for
the imputed nonresponse in this article. Descriptive
statistics were used to examine rates of response at
6 months.
Linear and logistic regression models were fit to esti-
mate the adjusted mean difference and odds ratios
(ORs) as appropriate with 95% CIs comparing response
rates in TCZ initiators with ABA initiators. The result-
ing regression models were adjusted considering the
matched-pair as a random effect (e.g., patient clustered
within the matched pair). Using the stratified-matching
strategy, all of the baseline characteristics had standard-
ized differences < 0.1. No additional covariates were
therefore used in the models. Safety outcomes were also
compared between the two groups. Specifically, we
assessed all cancers (excluding nonmelanoma skin can-
cer), infections (all infections and serious infections, de-
fined as those infections requiring hospitalization or
intravenous antibiotics), and cardiovascular events (in-
cluding myocardial infarction, stroke, acute coronary
syndrome, coronary artery disease, congestive heart
failure, peripheral arterial disease, and hypertension) re-
ported by the providers over the 6-month period. We
used a time to event approach to obtain the rate of
events for each category of adverse event based on the
available person-time.
Fig. 1 Flow diagram for tocilizumab (TCZ) and abatacept (ABA) initiators based on the study criteria. No prior comparison drug means the TCZ
patients had no prior exposure to ABA and the ABA patients had no prior exposure to TCA. CDAI Clinical Disease Activity Index, Mod moderate,
RA rheumatoid arthritis, TNF tumor necrosis factor
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Results
Baseline demographics
A total of 663 ABA and 264 TCZ initiators met the
inclusion criteria prior to implementation of the pro-
pensity scores (Fig. 1). Over the 6-month period most
initiators stayed on the medication (92.3% ABA and
89.0% TCZ were persistent), with switching (5.7%
ABA and 7.6% TCZ) and discontinuation without ini-
tiating another biologic (2.0% ABA and 3.4% TCZ)
occurring in the minority of patients. Comparison of
the two treatment arms revealed differences (stan-
dardized differences > 0.1) in terms of the proportion
of women, history of prior infections, patient and glo-
bal assessments of disease activity, and number of
prior biologics (Table 1). The two treatment arms
were then stratified and propensity score matched
(1:1), resulting in 264 participants each in the two
arms (44.7% with one prior TNFi and 55.3% with ≥2
prior TNFis). There were no substantial differences in
the baseline characteristics of the two groups defined
as standardized differences > 0.1 in the stratified
matched sample, as shown in Table 1, and thus ad-
justed analyses were not required. Overall persistency
was similar with the median time from initiation to
discontinuation 17.7 months (13.6, 23.9) in ABA users
as compared with 17.9 months (13.7, 27.2) in TCZ
users (p = 0.81). Most patients were female, in their
mid-50s, with approximately a decade of disease dur-
ation, and had high disease activity at the time of
drug initiation with 10 tender joints and seven swol-
len joints. Just over half (52%) of both groups were
receiving methotrexate (with a mean dose of 17.1 mg
(SD 5.1) in ABA users and 18.7 mg (SD 5.1) in TCZ
users). Similar percentages of patients remained on
drug (95.5% ABA vs 89.0% TCZ), switched biologics
(6.8% ABA vs 7.6% TCZ), or discontinued biologics
altogether (2.7% ABA vs 3.4% TCZ) over the study
period. At initiation, 85% of ABA users received
intravenous infusions and 15% received subcutaneous
medication. In the TCZ initiators, 83% received intra-
venous infusions and 17% received subcutaneous
injections.
Outcomes at 6 months
Mean change in CDAI at 6 months in the stratified pro-
pensity score-matched treatment groups were similar: –
11.3 ± 14.7 in the ABA initiators vs –9.9 ± 14.1 in the
TCZ initiators (Table 2). The difference was –1.27 (95%
CI –3.65 to 1.11) for ABA use as compared with TCZ.
Achievement of LDA/remission occurred in 1/3 of pa-
tients in both groups with an OR of 0.99 (95% CI 0.69,
1.43). Similarly, the change in mHAQ was –0.12 ± 0.42
for ABA and –0.11 ± 0.49 for TCZ, resulting in a differ-
ence of –0.01 (95% CI –0.09, 0.06).
Use of concomitant prednisone and cDMARDs
There were no differences between the groups in terms
of change in prednisone dose. Most patients in both
treatment groups had no change in prednisone use over
the study period (68.7% ABA vs 67.2% TCZ). Dose in-
creases (either initiation or an increase of prednisone
dose) occurred in 12.6% of ABA vs 13.7% of TCZ users
while dose reduction (including discontinuation) oc-
curred in 18.7% ABA and 19.1% of TCZ users. At
6 months, 44.4% of ABA and 54.2% of TCZ users on
prednisone were receiving ≤5 mg/day (p = 0.21). Simi-
larly, cDMARD initiations (14.4% ABA vs 11.4% TCZ)
and discontinuations (15.2% ABA vs 13.3% TCZ) were
not different in the two groups.
Safety
The rates of AEs in the two populations are reported in
Table 3. The standardized rates per 100 person-years for
cancer, serious infection, and cardiovascular events in
ABA vs TCZ users were 1.2 vs 0.6, 2.5 vs 1.9, and 1.9 vs
2.5, respectively. No significant differences were ob-
served between the two groups.
Discussion
Using data from Corrona, a large US-based RA registry,
we compared the clinical effectiveness of TCZ vs ABA
among TNFi-experienced patients with moderate-to-high
disease utilizing patients from real-world rheumatology
practices. We compared change in disease activity,
achievement of LDA/remission as well as meaningful im-
provement in function in the two treatment groups. Both
treatments were effective for the primary outcome be-
cause the minimally clinical important difference for
change in CDAI is a reduction of 6 points for moderate
disease activity and 12 points for high disease activity [24].
Furthermore, we conducted a post-hoc analysis to evalu-
ate whether the dose of TCZ contributed to the results.
Specifically, there was no difference in terms of change in
CDAI, change in mHAQ, or achievement of LDA/remis-
sion among those on 4 mg/kg at the end of the study
period as compared with those who had escalated to
8 mg/kg (n = 182, 69%). Additionally, the safety of the two
agents was comparable over the study time period.
Our results are similar to an observational cohort
from Japan [19], in which investigators examined out-
comes in 102 matched pairs of patient treated with
TCZ at 8 mg/kg every 4 weeks vs ABA dosed based
on weight (500 mg for patients < 60 kg, 750 mg for
patients 60–100 kg, and 1000 mg for patients >
100 kg) at weeks 0, 2, and 4 and then every 4 weeks
after. They found no significant difference in reten-
tion rates between the two agents, which is consistent
with our findings (Additional file 1: Table S1). When
evaluating efficacy over 52 weeks using the SDAI they
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Table 1 Patient demographics and clinical characteristics at baseline by tocilizumab and abatacept initiators
Characteristic Unmatched Matched
TCZ Initiators ABA Initiators Standardized differencea TCZ Initiators ABA Initiators Standardized differencea
(n = 264) (n = 663) ABA – TCZ (n = 264) (n = 264) ABA – TCZ
Female, n (%) 197 (74.6) 547 (82.9) 0.2 197 (74.6) 197 (74.6) 0
Age, mean ± SD 56.6 ± 12.4 57.3 ± 12.3 0.05 56.6 ± 12.4 56.6 ± 12.2 –0.01
Race: White, n (%) 201 (76.1) 513 (77.4) 0.03 201 (76.1) 211 (79.9) 0.09
Smoker, n (%)
Never 119 (45.1) 305 (46.1) 0.07 119 (45.1) 115 (43.6) 0.03
Previous 90 (34.1) 237 (35.8) 90 (34.1) 94 (35.6)
Current 55 (20.8) 119 (18.0) 55 (20.8) 55 (20.8)
Insuranceb, n (%)
Private 205 (77.6) 516 (77.8) 0.01 205 (77.6) 193 (73.1) –0.1
Medicaid 12 (4.5) 34 (5.1) 0.03 12 (4.5) 14 (5.3) 0.03
Medicare 96 (36.4) 210 (31.7) –0.1 96 (36.4) 92 (34.8) –0.03
None 3 (1.1) 10 (1.5) 0.03 3 (1.1) 6 (2.2) 0.09
Duration of RA, mean ± SD 10.7 ± 8.8 11.1 ± 9.3 0.03 10.7 ± 8.8 10.3 ± 10.0 –0.03
RF/CCP seropositivity, n (%) 127 (76.5) 291 (74.1) –0.06 127 (76.5) 135 (73.7) –0.06
History of comorbidities, n (%)
Cardiovascular 43 (16.3) 88 (13.3) –0.08 43 (16.3) 41 (15.5) –0.02
Malignancy 14 (5.3) 37 (5.6) 0.01 14 (5.3) 16 (6.1) 0.03
Serious infection 18 (6.8) 67 (10.1) 0.12 18 (6.8) 23 (8.7) 0.07
Diabetes 26 (9.9) 64 (9.7) –0.01 26 (9.9) 33 (12.5) 0.08
mHAQ, mean ± SD 0.7 ± 0.5 0.6 ± 0.5 –0.16 0.7 ± 0.5 0.7 ± 0.5 0.02
CDAI, mean ± SD 27.8 ± 12.1 27.1 ± 11.9 –0.05 27.8 ± 12.1 28.1 ± 12.8 0.04
Tender joints, mean ± SD 10.3 ± 7.6 10.0 ± 7.2 –0.05 10.3 ± 7.6 10.4 ± 7.5 0.001
Swollen joints, mean ± SD 7.0 ± 4.9 7.4 ± 5.6 0.08 7.0 ± 4.9 7.3 ± 5.8 0.05
Physician global, mean ± SD 47.2 ± 20.4 43.8 ± 20.5 –0.16 47.2 ± 20.4 47.7 ± 20.9 0.02
Patient global, mean ± SD 57.0 ± 23.6 53.2 ± 23.9 –0.16 57.0 ± 23.6 56.8 ± 23.3 0
Patient pain, mean ± SD 58.6 ± 24.6 55.9 ± 25.4 –0.1 58.6 ± 24.6 58.3 ± 25.5 –0.01
ACR functional status, n (%)
I 55 (20.8) 200 (30.2) 55 (20.8) 48 (18.2)
II 130 (49.2) 306 (46.2) 0.23 130 (49.2) 138 (52.3) 0.07
III/IV 79 (29.0) 157 (23.7) 79 (29.9) 78 (29.5)
Prednisone use, n (%)
None 166 (63.4) 415 (63.1) 166 (63.4) 168 (63.9)
<10 mg 53 (20.2) 144 (21.9) 0.04 53 (20.2) 50 (18.8) 0.03
≥10 mg 43 (16.4) 99 (15.1) 43 (16.4) 44 (16.5)
Number of prior biologics used, n (%)
1 99 (37.5) 261 (39.4) 0.12 99 (37.5) 109 (41.3) –0.08
2 94 (35.6) 257 (38.8) 165 (62.5) 155 (58.7)
3+ 71 (26.9) 145 (21.8)
Concomitant use of cDMARD, n (%) 180 (68.2) 456 (68.8) 0.01 180 (68.2) 179 (67.8) –0.01
aA standard difference < 0.1 has been taken to indicate a negligible difference in the mean or prevalence of a covariate between treatment groups
bpatients may have more than 1 type of insurance
ABA abatacept, ACR American College of Rheumatology, CCP cyclic citrullinated peptide, CDAI Clinical Disease Activity Index, cDMARD conventional disease-
modifying anti-rheumatic agent, mHAQ modified health assessment questionnaire, RA rheumatoid arthritis, RF rheumatoid factor, TCZ tocilizumab
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identified no differences between the two agents, with ap-
proximately 46–50% achieving LDA/remission at 6 months
and 47–55% at 12 months. These rates are slightly higher
than our study, but this may be in part be due to differ-
ences in the outcome measure used, patient characteris-
tics, and study design. Of note, the patients in our cohort
had higher baseline disease activity based on the CDAI.
Furthermore, Corrona’s registry reflects real-world prac-
tice. Physicians may thus administer medications at doses
and frequencies different from the package labeling (e.g.,
holding doses for procedures or hospitalizations). Add-
itionally, we included patients in the analyses regardless of
whether they switched to another biologic or discontinued
the agent without starting a new biologic. With respect to
functional impairment, both studies showed no difference
between the treatment groups (ours using mHAQ scores
and the Japanese cohort using HAQ-DI scores).
We additionally examine the impact of concomitant
RA medications on our findings. This included an evalu-
ation as to whether there were differences in the use of
prednisone (both initiation and dose escalation) and
cDMARDs (initiation and discontinuation) between the
two groups. No such differences were found (Additional
file 1: Tables S2 and S3). We also explored whether our
selection approach influenced the results. We found
similar outcomes in ABA patients who were not selected
for inclusion into the study (because of receipt of the
medication prior to the availability of TCA) to the ABA
patients who were included.
We believe that comparative effectiveness studies of
non-TNF biologics are needed for practicing rheumatol-
ogists when trying to decide which agents to prescribe
in their patients with prior TNFi exposure. Rheumatolo-
gists want to prescribe the right drug to the right patient
at the right time. Providing comparative data with ac-
companying safety information is essential for rheuma-
tologists in order to facilitate patients achieving the best
clinical outcomes. Given the lack of head-to-head RCTs,
observational studies are the best approach for evaluat-
ing comparative treatment outcomes. Using “best prac-
tice” approaches, propensity score methodology was
used specifically due to selection bias. Based on these
findings, both agents were associated with substantial
improvement in RA symptoms. The individual choice of
which agent to prescribe will likely be informed based
on patient characteristics, pharmacy benefit plan, and
patient preference.
This study had several strengths. It is the largest
known comparative effectiveness study of ABA vs TCZ
in the United States and included a nationwide sampling
of patients with RA. The all-comers study design re-
cruited individuals from multiple rheumatology centers,
resulting in a range of patients with real-world disease
activity and comorbidities not often seen in RCTs. We
Table 3 Rates of cancers, infection (overall and serious infections), and cardiovascular adverse events
Adverse event rates, events/100 PY
Tocilizumab Abatacept Ratio (95% CI) of rates
tocilizumab/abatacept
p value
Cancera 0.61 events/155.2 PY 1.22 events/157.2 PY 0.5 (0.1, 9.7) 0.63
Infection
All events 54.373 events/135.4 PY 57.179 events/138.3 PY 0.9 (0.7, 1.3) 0.72
Serious infections 1.93 events/155.2 PY 2.54 events/157.7 PY 0.7 (0.1, 4.5) 0.74
Cardiovascular 2.54 events/154.6 PY 1.93 events/156.7 PY 1.3 (0.2, 9.2) 0.71
aExcluding nonmelanoma skin cancer
CI confidence interval, PY person-years
Table 2 Comparison between tocilizumab and abatacept initiators in terms of mean change in CDAI, mean change in mHAQ, and
achievement of low disease activity from baseline to 6 months
Outcome Tocilizumab initiators
(n = 264)
Abatacept initiators
(n = 264)
Unadjusted differencea abatacept
vs tocilizumab
Continuous Mean ± SD Mean ± SD β (95% CI) p value
Change in CDAI n = 259, –9.9 ± 14.1 n = 257, –11.3 ± 14.7 –1.27 (–3.65, 1.11) 0.30
Change in mHAQ n = 263, –0.11 ± 0.49 n = 264, –0.12 ± 0.42 –0.01 (–0.09, 0.06) 0.83
Binary Response rate Response rate OR (95% CI) p value
Achievement of LDA n = 259 n = 257
(CDAI at time of switch was imputed for switchers) 86 (33.2%) 85 (33.1%) 0.99 (0.69, 1.43) 0.97
aMatched pair as the random effect
CDAI Clinical Disease Activity Index, CI confidence interval, LDA low disease activity, mHAQ modified Health Assessment Questionnaire, OR odds ratio
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also evaluated effectiveness by examining response in all
patients regardless of continuation of initial treatment.
This has been shown to provide a conservative estimate
[15]. Additionally, we examined comparative effective-
ness broadly with evaluation of response using the
CDAI, function using the mHAQ, and safety between
the two drug-exposure cohorts because all three ele-
ments are needed for clinical decision-making.
This study also had some limitations related to the
challenges of operationalizing available, real-world data,
and applying analytical methods conservatively. As with
any registry, there is a concern that patient enrollment
may not reflect the type of patients observed elsewhere
in general practice. However, a previous study [25] dem-
onstrated that Corrona RA patients enrolled in Medicare
shared similar demographic and clinical characteristics
to the national cohort of RA patients based on Medicare
rheumatology-based claims. Of note, we only had suffi-
cient sample size to explore 6-month outcomes. Poten-
tially a longer time frame may have demonstrated
differences. Also, as in any observational study, bias is a
concern because physicians prescribe therapies based on
the patient’s profile and treatment selection is not ran-
dom. To overcome this limitation, we matched by pro-
pensity score and stratified by prior TNFi. However, this
method does not address unmeasured confounders. We
did include patients in the analyses who discontinued
ABA or TCZ (<4% in each group) without initiating a
subsequent biologic because the reason for discontinu-
ation was not clear (e.g., drug holiday due to a good re-
sponse to the medication, side effects, out-of-pocket
costs, etc.). Because there was no significant difference
between groups in discontinuation rates, however, the
outcome of the study (i.e., no difference in clinical re-
sponse between the two drugs) would not be altered if
we excluded these patients from the analyses. Because of
sample size considerations, sensitivity analyses were not
performed based on reasons for discontinuation of the
prior TNFi, although other studies have shown that this
can influence treatment response [26].
Conclusions
Among patients with prior exposure to TNFi, use of
ABA and TCZ both resulted in improved disease activity
based on the MCID of the CDAI and function as mea-
sured with the mHAQ. Furthermore, the safety profiles
of the two treatments were similar over the 6-month
time frame. Based on these findings, the results suggest
that both agents would be appropriate choices as the
next therapeutic agent in patients with moderately-to-
severely active RA with prior exposure to TNFis. Further
analyses are necessary to better identify the patient sub-
sets likely to respond to a particular agent.
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distribution of prednisone dose increases and decreases between the
matched TCA and ABA initiators based on the baseline prednisone
usage. Table S3 presents rates of discontinuation and initiation of
cDMARDs over the 6-month follow-up. (DOCX 14 kb)
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